NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it expects to meet its planned launch date for its latest product, NC-stat^®|DPNCheck™, which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). The marketing launch will occur during the exhibition at the American Diabetes Association 71^st Scientific Sessions in San Diego, CA on June 24-28, 2011.

NC-stat DPNCheck measures sural nerve conduction velocity and amplitude, which are standard biomarkers for DPN. The device is a modified version of the widely used NC-stat^® device which has been shown to accurately detect DPN. Potential clinical benefits of sural nerve conduction obtained at the point-of-care include:

• Early detection of DPN, even in the absence of clinical symptoms and signs
• Help with confirmation or rule-out of DPN and quantification of severity
• Monitoring changes in DPN over time and in response to treatment

NC-stat DPNCheck will be commercially available in the second half of the year. To learn more, click here.

The Company has a number of activities scheduled during the American Diabetes Association 71^st Scientific Sessions. This includes presentation of two posters from accepted abstracts, live demonstrations of NC-stat DPNCheck, and a meeting of its diabetes scientific advisory board (SAB). The SAB has played an important role in guiding the development of NC-stat DPNCheck, and includes:

• David G. Armstrong, DPM, MD, PhD
• Andrew J.M. Boulton, MRCP (UK), MD, FRCP
• Neil H. Brooks, MD, FAAFP
• Bruce A. Perkins, MD, MPH, FRCP(C)
• Solomon Tesfaye, MB, ChB, MD, FRCP (UK)
• Aaron I. Vinik, MD, PhD, FCP, FACP
• Dan Ziegler, MD, FRCPE